Version history

{
  "session_id": "sess_SDA-2026-04-15-gap-debate-20260410-112330-9abf86eb_20260415-165431",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Skeptic's Critique: Astrocytic Ketone Therapeutic Window Hypotheses\n\n---\n\n## Hypothesis 1: Astrocytic MCT1/MCT2 Transport Capacity as Window Gatekeeper\n\n### Strongest Specific Weakness: Conflation of Ketone Production vs. Export\n\nThe research question defines the window by **astrocytic ketone *production*** declining, yet this hypothesis centers on MCT1-mediated **export**. These are mechanistically distinct. The hypothesis cannot explain *why* ketone production declines in the first place—it only addresses the transport barrier once ketones exist. If production itself is the primary defect (e.g., reduced HMG-CoA synthase II activity), MCT1 augmentation addresses only the downstream logistics.\n\n### Counter-Evidence and Complications\n\n1. **Species-specific BBB physiology complicates translation.** The predominant ketone transporter at the human blood-brain barrier is MCT1 on endothelial cells, not astrocytic MCT1 (PMID: 24523872). The cited evidence (PMID: 26753690) using astrocyte-specific deletion in mice may not capture the physiologically rate-limiting step in humans.\n\n2. **Exogenous ketone delivery bypasses the gatekeeper.** If systemic βOHB is administered, it enters neurons directly from blood through BBB MCT1, not via astrocytic export. The therapeutic window predicted by this model becomes incoherent when the intervention itself circumvents the bottleneck being proposed as the window's defining feature.\n\n3. **MCT1 loss-of-function is pleiotropic.** MCT1 also transports lactate. Astrocyte-specific deletion may impair the astrocytic lactate shuttle critical for synaptic metabolism (PMID: 24204816), causing cognitive decline through a distinct mechanism than ketone deficiency, contaminating the experimental read-out.\n\n### Pointed Question\n\nIf you delete astrocyte-specific *Slc16a1* and observe accelerated cognitive decline at 6 months, how do you distinguish **\"therapeutic window for ketone-based intervention has closed earlier\"** from **\"loss of MCT1 causes general astrocytic metabolic failure that worsens neurodegeneration regardless of ketone availability\"**? The experimental readout conflates two separable phenomena.\n\n### Confidence Rating: **Moderate**\n\nThe transport logic is mechanistically plausible, and the cited PMIDs support real effects of MCT1/MCT2 on brain ketone utilization. However, the hypothesis as stated fails to address the *production* component of the research question and lacks specificity about temporal dynamics relative to",
  "tokens_used": "624"
}